The high cost of new, innovative cancer treatments coming to market makes these therapies inaccessible to a lot of patients, said Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.
The high cost of new, innovative cancer treatments coming to market makes these therapies inaccessible to a lot of patients, said Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.
Transcript
What impact will new, potentially curative therapies have financially on patients and the healthcare system?
New, innovative treatments that are coming on the market are wonderful. But, if patients can’t access them then they are ineffective. These new treatments that are coming, I don’t really see what we’re seeing with how much they are costing but I don’t see them as accessible to a lot of these patients unless you have really good coverage. It depends on the benefit design and it depends on the medication. So, if it does fall under their medical, and if they are able to get it through their hospital coverage it may be affordable.
I don’t really know enough about the CAR Ts, but from the few that have come to market they are with a pretty heavy price tag. Although, if they are successful, they have the potential of really saving lives. I think the jury is still out on how that will affect patients and how accessible.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More